Evidence map›Paper›PMID 41130074›Full record

ArticleBioorganic & medicinal chemistry2026

Halogenated N-(1,3,4-oxadiazol-2-yl) benzamides are effective eradicators of methicillin-resistant Staphylococcus aureus biofilms.

George A Naclerio, Christopher S Vennard, Kenneth I Onyedibe, Dielson da S Vieira, Nader S Abutaleb, Marxa L Figueiredo, Mohamed N Seleem, Herman O Sintim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

George A NaclerioChemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, United States.
Christopher S VennardChemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, United States; Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, United States.
Kenneth I OnyedibeChemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, United States.
Dielson da S VieiraChemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, United States; Basic Medical Sciences, Purdue University, College of Veterinary Medicine, West Lafayette, IN 47907, United States.
Nader S AbutalebDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA 24060, United States.
Marxa L FigueiredoBasic Medical Sciences, Purdue University, College of Veterinary Medicine, West Lafayette, IN 47907, United States.
Mohamed N SeleemDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA 24060, United States; Center for Emerging, Zoonotic and Arthropod-borne Pathogens, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, United States.
Herman O SintimChemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, United States; Purdue Institute of Inflammation, Immunology, and Infectious Disease, West Lafayette, IN 47907, United States; Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, United States. Electronic address: hsintim@nd.edu.

Funding

Repurposing auranofin and ebselen for treatment of multidrug resistant pathogensR01AI130186 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI SELEEM, MOHAMED · 2017 to 2021
$2.3M
Drug Discovery in Infectious Disease TrainingT32AI148103 · NIAID · PURDUE UNIVERSITY · PI STAHELIN, ROBERT VIRGIL, YEO, YOON · 2020 to 2024
$949k
NIAID NIH HHS R01 AI130186NIAID NIH HHS T32 AI148103
6 · The paper itself

Abstract

Due to the ever-increasing threat of methicillin-resistant Staphylococcus aureus (MRSA), we have embarked on a campaign to discover novel antibacterial agents which are effective at eradicating both MRSA, as well as acting on pre-formed MRSA biofilms. Using the known scaffold of N-(1,3,4-oxadiazol-2-yl)benzamides, we performed a halogenation study which has led to the identification of HSGN-2241. This novel compound was found to effectively kill many multi-drug resistant Gram-positive clinical isolates in a bactericidal manner. The growth inhibition mechanism of HSGN-2241 was found to be via potassium ion release and subsequent depolarization of the cell membrane. As an initial safety test, HSGN-2241 was found to not lyse human red blood cells, so it is a promising lead compound for the treatment of bacterial infections caused by Staphylococcus aureus.

Indexed as

Anti-Bacterial AgentsBenzamidesBiofilmsMethicillin-Resistant Staphylococcus aureusOxadiazolesDose-Response Relationship, DrugHalogenationHumansMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipAnti-Bacterial AgentsBenzamidesOxadiazolesBiofilmDrug resistanceMembrane depolarizersMRSAN-(1,3,4-oxadiazol-2-yl) benzamides

Identifiers

PMID41130074
PMCPMC13283350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.